Statistiche di base
| LEI | 549300GX8Y96GSB6YP89 |
| CIK | 1162194 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Standard BioTools Inc
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 28, 2025 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34180 (Commission File Number |
|
| August 15, 2025 |
Calculation of Filing Fee Tables S-8 STANDARD BIOTOOLS INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock $0.001 par value per share 457(a) 17,400,000 $ 1.2675 $ 22,054,500.00 0.0001531 $ 3,376.54 Total |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STANDARD B |
|
| August 15, 2025 |
Exhibit 10.1 OMNIBUS AMENDMENT RE COLLABORATION AGREEMENT This Omnibus Amendment re Collaboration Agreement (the “Amendment”) is effective as of date of last signature below (the “Omnibus Amendment Effective Date”) by and among Illumina Cambridge, Ltd., a private company limited by shares organized under the laws of England and Wales, with an address at Illumina Centre, 19 Granta Park, Great Abing |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025 As filed with the Securities and Exchange Commission on August 15, 2025 Registration No. |
|
| August 12, 2025 |
SEC FILE NUMBER 001-34180 CUSIP NUMBER 34385P108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 11, 2025 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Commis |
|
| August 11, 2025 |
Standard BioTools Reports Second Quarter 2025 Financial Results Exhibit 99.1 Standard BioTools Reports Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., August 11, 2025 - Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2025 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34180 (Commission File Number) |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 22, 2025 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation or organization |
|
| June 23, 2025 |
Exhibit 2.1 Execution Version CERTAIN INFORMATION CONTAINED IN THIS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE IT IS BOTH: (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STOCK PURCHASE AGREEMENT dated as of June 22, 2025 by and between ILLUMINA, INC. and STANDARD BIOTOOLS INC. TABLE OF CONTEN |
|
| June 23, 2025 |
Exhibit 99.1 Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating Structure and Enables Achievement of Adjusted |
|
| June 20, 2025 |
Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan, as Amended. Exhibit 10.1 STANDARD BIOTOOLS INC. EQUITY INCENTIVE PLAN (as amended and restated effective June 3, 2019, and as further amended effective June 23, 2020, May 25, 2021, June 14, 2023, January 4, 2024, June 27, 2024 and June 18, 2025) 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to prov |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 18, 2025 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34180 (Commission File Number) |
|
| June 2, 2025 |
Standard BioTools Inc. Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Standard BioTools Inc. Conflict Minerals Report For The Reporting Period from January 1, 2024 to December 31, 2024 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Standard BioTools Inc.’s objectives for i |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Standard BioTools Inc. (Exact name of the registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34180 (Commission File Number) 77-0513190 (IRS Employer Identification No.) 2 Tower Place, Suite 2000, South San Francisco, California (Address of p |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 6, 2025 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Commission |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STANDARD |
|
| May 6, 2025 |
Standard BioTools Reports First Quarter 2025 Financial Results Exhibit 99.1 Standard BioTools Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 06, 2025 - Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: • First quarter 2025 revenue of $40.8 million • 45% reduction in operating loss and 29% improvement in adju |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 30, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant |
|
| March 11, 2025 |
Exhibit 10.38 Join an innovative team driven by a bold vision – unleashing tools to accelerate breakthroughs in human health™ May 10, 2024 Sean Mackay Los Angeles, California Dear Sean: We are pleased to offer you the position of SVP & Chief Business Officer with Standard BioTools Inc, reporting directly to Michael Egholm, Chief Executive Officer and President. You will perform work duties from yo |
|
| March 11, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Standard BioTools, Inc. (“Standard BioTools,” “we,” “us,” “our,” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common stock, par value $0.001 per |
|
| March 11, 2025 |
Standard BioTools Inc. Insider Trading Policy STANDARD BIOTOOLS INC. INSIDER TRADING POLICY (Effective August 1, 2023) Exhibit 19.1 i TABLE OF CONTENTS Page The Need for an Insider Trading Policy........................................................................................... 1 What is Material Non-Public Information? ..................................................................................... 1 The Consequences of Insider |
|
| March 11, 2025 |
Subsidiaries of Standard BioTools Inc. 10 Exhibit 21.1 SUBSIDIARIES OF STANDARD BIOTOOLS INC. Subsidiaries of Standard BioTools Inc. (Delaware): SB Sciences Inc. (Delaware) Standard BioTools Australia Pty. Ltd. (Australia) Standard BioTools (Shanghai) Instrument Technology Company Limited (China) Standard BioTools K.K. (Japan) Standard BioTools Europe B.V. (Netherlands) Standard BioTools Singapore Pte. Ltd. (Singapore) SomaLogic, Inc. |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 26, 2025 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Comm |
|
| February 26, 2025 |
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., February 26, 2025 — Standard BioTools Inc. (NASDAQ: LAB) (the "Company” or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: • Full year 2024 pro forma combined revenue of $175.1 million • 17% |
|
| January 13, 2025 |
Exhibit 99.1 Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., January 13, 2025 - Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” o |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 13, 2025 |
Exhibit 99.2 Setting Standards Empowering Research Building Shareholder Value Investor Presentation January 2025 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements o |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 3, 2025 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Commis |
|
| December 20, 2024 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Plaintiffs, v. ELI CASDIN, TROY COX, THOMAS CAREY, JASON RYAN, and CASDIN CAPITAL, LLC, Defendants. DR. LARRY GOLD and ) DR. JASON CLEVELAND, on behalf ) of themselves and all similarly situated ) former stockholders of SomaLogic, Inc., ) ) ) ) ) ) ) ) ) ) ) ) C.A. No. 2023-1249-SG STIPULATION AND [PROPOSED] ORDER GOVERNING PLAINTIFFS’ MOTION FOR A |
|
| December 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 19, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Comm |
|
| November 14, 2024 |
LAB / Standard BioTools Inc. / Indaba Capital Management, L.P. Passive Investment SC 13G/A 1 formsc13ga-standard.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Standard BioTools Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| November 7, 2024 |
Standard BioTools Appoints Alex Kim as Chief Financial Officer Exhibit 99.1 Standard BioTools Appoints Alex Kim as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., November 7, 2024 - Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Commi |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STAND |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 30, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Commi |
|
| October 30, 2024 |
Standard BioTools Reports Third Quarter 2024 Financial Results Exhibit 99.1 Standard BioTools Reports Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., October 30, 2024 - Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: • Reported third quarter 2024 revenue of $45 million • Ongoing merger cost synergy realization delivered |
|
| October 21, 2024 |
LAB / Standard BioTools Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 LABSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) STANDARD BIOTOOLS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 34385P108 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropr |
|
| September 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 5, 2024 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 5, 2024 |
Exhibit 99.1 Standard BioTools 1 Unleashing Tools to Accelerate Breakthroughs in Human Health INVESTOR PRESENTATION September 2024 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2024 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 30, 2024 |
2024 Change of Control and Severance Plan and Participation Agreement. Exhibit 10.1 STANDARD BIOTOOLS INC. 2024 CHANGE OF CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Adopted August 27, 2024 1. Introduction. The purpose of this Standard BioTools Inc. 2024 Change of Control and Severance Plan, or Plan (as defined in Section 2 below), is to provide assurances of specified benefits to certain employees of the Company whose employment is subject to |
|
| August 14, 2024 |
LAB / Standard BioTools Inc. / Casdin Capital, LLC Activist Investment SC 13D/A 1 d1144457813d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Standard BioTools Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) Eli Casdin Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Standard BioTools Inc. |
|
| August 6, 2024 |
Standard BioTools Inc. Nonemployee Director Compensation Policy. Exhibit 10.2 STANDARD BIOTOOLS INC. NONEMPLOYEE DIRECTOR COMPENSATION POLICY (Adopted April 25, 2024) The Board of Directors of Standard BioTools Inc. (the “Company”) has approved the following Nonemployee Director Compensation Policy (this “Policy”) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors. The Policy e |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STANDARD B |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 31, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Commissi |
|
| July 31, 2024 |
Exhibit 99.1 Standard BioTools Announces Senior Leadership Changes Alex Kim, Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business Officer SOUTH SAN FRANCISCO, Calif., July 31, 2024 - Standard BioTools Inc. (“Standard BioTools” or the “Company”) |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2024 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 31, 2024 |
Exhibit 99.1 Standard BioTools Reports Second Quarter 2024 Financial Results Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents, restricted cash and short-term |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2024 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 1, 2024 |
Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan, As Amended. Exhibit 10.1 STANDARD BIOTOOLS INC. EQUITY INCENTIVE PLAN (as amended and restated effective June 3, 2019, and as further amended effective June 23, 2020, May 25, 2021, June 14, 2023, January 4, 2024 and June 27, 2024) 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide |
|
| June 25, 2024 |
Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA June 25, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Nicholas O'Leary RE: Standard BioTools Inc. Registration Statement on Form S-3 |
|
| June 20, 2024 |
Exhibit 99.1 SomaLogic, Inc. Consolidated Financial Statements As of and for the years ended December 31, 2023 and 2022 With report of Independent Auditors Table of Contents Page Report of Independent Auditors F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations and Comprehensive Loss F-5 Consolidated Statements of Stockholders’ Equity F-6 Consolidated Statements of Cash Flows |
|
| June 20, 2024 |
Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On January 5, 2024 (the “Closing Date”), Standard BioTools Inc. ("Standard BioTools" or the “Company”) completed the merger (the "Effective Time") pursuant to the Agreement and Plan of Merger, dated as of October 4, 2023 (the “Merger Agreement”), by and among Standard BioTools, SomaLogic, Inc. ("SomaLogic") and Martis Merger |
|
| June 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Standard BioTools Inc. |
|
| June 20, 2024 |
As filed with the Securities and Exchange Commission on June 18, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 18, 2024 Registration No. |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 3, 2024 |
LAB / Standard BioTools Inc. / Casdin Capital, LLC Activist Investment SC 13D/A 1 d1106538613d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Standard BioTools Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) Eli Casdin Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 31, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation or organization) |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Standard BioTools Inc. (Exact name of the registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation (Commission File Number) (IRS Employer Identification No.) 2 Tower Place, Suite 2000, South San Francisco, California 94080 (Address |
|
| May 29, 2024 |
Standard BioTools Inc. Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Standard BioTools Inc. Conflict Minerals Report For The Reporting Period from January 1, 2023 to December 31, 2023 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Standard BioTools Inc.’s objectives for i |
|
| May 22, 2024 |
LAB / Standard BioTools Inc. / Casdin Capital, LLC Activist Investment SC 13D/A 1 d1105718313d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Standard BioTools Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) Eli Casdin Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 |
|
| May 21, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| May 20, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 10, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STANDARD |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Commission |
|
| May 8, 2024 |
Exhibit 99.1 Standard BioTools Reports First Quarter 2024 Financial Results • Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 • Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of approximately $21 million, and non |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exac |
|
| April 26, 2024 |
Standard BioTools Inc. Nonemployee Director Compensation Policy. Exhibit 10.96 STANDARD BIOTOOLS INC. NONEMPLOYEE DIRECTOR COMPENSATION POLICY (Adopted April 25, 2024) The Board of Directors of Standard BioTools Inc. (the “Company”) has approved the following Nonemployee Director Compensation Policy (this “Policy”) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors. The Policy |
|
| April 25, 2024 |
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth Exhibit 99.1 Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth · Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025 · Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call South San Francisco, Calif., April 25, 2024 - Standard Bio |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 20, 2024 |
LAB / Standard BioTools Inc. / Casdin Capital, LLC Activist Investment SC 13D/A 1 d1100725313d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Standard BioTools Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) Eli Casdin Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 |
|
| March 20, 2024 |
LAB / Standard BioTools Inc. / VIKING GLOBAL INVESTORS LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Standard BioTools Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 34385P108 (CUS |
|
| March 18, 2024 |
Certificate of Elimination of Series B-2 Convertible Preferred Stock. Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES B-2 CONVERTIBLE PREFERRED STOCK OF STANDARD BIOTOOLS INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Standard BioTools Inc., a Delaware corporation (the “Company”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, hereby certifies as follows: That p |
|
| March 18, 2024 |
Exhibit 10.1 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”) is made as of March 18, 2024, by and among (a) Standard BioTools Inc., a Delaware corporation (the “Company”), (b) Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (collectively, the “Casdin Investors”) and (c) Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global O |
|
| March 18, 2024 |
Certificate of Elimination of Series B-1 Convertible Preferred Stock. Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES B-1 CONVERTIBLE PREFERRED STOCK OF STANDARD BIOTOOLS INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Standard BioTools Inc., a Delaware corporation (the “Company”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, hereby certifies as follows: That p |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 18, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation or organisatio |
|
| March 18, 2024 |
Exhibit 99.1 Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock SOUTH SAN FRANCISCO, Calif., March 18, 2024 - Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common st |
|
| March 1, 2024 |
Subsidiaries of Standard BioTools Inc. Exhibit 21.1 SUBSIDIARIES OF STANDARD BIOTOOLS INC. Subsidiaries of Standard BioTools Inc. (Delaware): SB Sciences Inc. (Delaware) Standard BioTools (Shanghai) Instrument Technology Company Limited (China) Standard BioTools K.K. (Japan) Standard BioTools Europe B.V. (Netherlands) Standard BioTools Singapore Pte. Ltd. (Singapore) SomaLogic, Inc. (Delaware) Subsidiaries of Standard BioTools Europe B |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant |
|
| March 1, 2024 |
Standard BioTools Inc. Clawback Policy. Exhibit 97.1 STANDARD BIOTOOLS INC. CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Standard BioTools Inc.(the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has there |
|
| March 1, 2024 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Standard BioTools, Inc. (“Standard BioTools,” “we,” “us,” “our,” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common stock, par value $0.001 per |
|
| March 1, 2024 |
Exhibit 10.2 STANDARD BIOTOOLS INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 2024 by and between Standard BioTools Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”). WHEREAS, the Company and Indemnitee recognize the significant cost of directors’ and officers’ liability insurance and the general reductions in the coverage of such |
|
| March 1, 2024 |
Standard BioTools Inc. Amended and Restated Outside Director Equity Compensation Policy. Exhibit 10.96 STANDARD BIOTOOLS INC. Outside Director Equity Compensation Policy (as amended and restated effective August 9, 2022) Standard BioTools Inc. (the “Company”) believes that the granting of equity compensation represents a powerful tool to attract, retain and reward members of its board of directors who are not Employees (“Outside Directors”) and to align the interests of our Outside Di |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Comm |
|
| February 28, 2024 |
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results • Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins • Completed merger with SomaLogic, activating strategy to build scaled leader in life sciences tools and services • Combined pro forma revenue for FY2023 |
|
| February 26, 2024 |
LAB / Standard BioTools Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 LABSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 STANDARD BIOTOOLS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 34385P108 (CUSIP Number) FEBRUARY 16, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate t |
|
| February 14, 2024 |
FLDM / Standard BioTools Inc / Indaba Capital Management, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Standard BioTools Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 13, 2024 |
FLDM / Standard BioTools Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01983-standardbiotoolsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Standard BioTools Inc Title of Class of Securities: Common Stock CUSIP Number: 34385P108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuan |
|
| February 5, 2024 |
Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA February 5, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin RE: Standard BioTools Inc. Registration Statement on Form S-3, as amended File No. 333-276628 Request f |
|
| February 5, 2024 |
Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA February 5, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin RE: Standard BioTools Inc. Registration Statement on Form S-3 File No. 333-276626 Request for Accelerat |
|
| February 2, 2024 |
As filed with the Securities and Exchange Commission on February 2, 2024 As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. |
|
| January 19, 2024 |
Form of 2014 Non-Statutory Stock Option Agreement. Exhibit 99.4 SOMALOGIC, INC. Non-Statutory Stock Option Agreement SomaLogic, Inc. (the “Company”) hereby grants an Option to purchase shares of the Company’s common stock to you, the Optionee named below. This Option is being granted outside of the Company’s 2009 Equity Incentive Plan (the “Plan”), but this Agreement will incorporate provisions of the Plan by reference. In addition, capitalized te |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
Exhibit 99.1 Item 8. Financial Statements and Supplementary Data Index to Financial Statements Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) 2 Consolidated Balance Sheets 3 Consolidated Statements of Operations and Comprehensive Loss 4 Consolidated Statements of Stockholders’ Equity 5 Consolidated Statements of Cash Flows 6 Notes to Consolidated Financial Statements N |
|
| January 19, 2024 |
PART 1 – FINANCIAL INFORMATION Exhibit 99.2 PART 1 – FINANCIAL INFORMATION Item 1. Financial Statements SomaLogic, Inc. Condensed Consolidated Balance Sheets Unaudited (in thousands, except share data) September 30, 2023 December 31, 2022 ASSETS Current assets Cash and cash equivalents $ 305,571 $ 421,830 Investments 148,239 117,758 Accounts receivable, net 20,730 17,006 Inventory 13,884 13,897 Deferred costs of services 379 1, |
|
| January 19, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2024 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Standard BioTools Inc. |
|
| January 19, 2024 |
Form of Non-Statutory Stock Option Agreement. Exhibit 99.5 SOMALOGIC, INC. Non-Statutory Stock Option Agreement SomaLogic, Inc. (the “Company”) hereby grants to you, the Optionee named below, a Stock Option to purchase shares of the Company’s Class B common stock, par value $.01 per share, (the “Option”), pursuant to the terms and conditions of this Non-Statutory Stock Option Agreement, consisting of this cover page and the Option Terms and C |
|
| January 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Standard BioTools Inc. |
|
| January 19, 2024 |
Form of Non-Statutory Stock Option Agreement. Exhibit 99.4 SOMALOGIC, INC. Non-Statutory Stock Option Agreement SomaLogic, Inc. (the “Company”) hereby grants to you, the Optionee named below, a Stock Option to purchase shares of the Company’s Class B common stock, par value $.01 per share, (the “Option”), pursuant to the terms and conditions of this Non-Statutory Stock Option Agreement, consisting of this cover page and the Option Ter |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
STANDARD BIOTOOLS AND SOMALOGIC UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 STANDARD BIOTOOLS AND SOMALOGIC UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On October 4, 2023, Standard BioTools Inc. (“Standard BioTools”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with SomaLogic, Inc. (“SomaLogic”) and Martis Merger Sub Inc. (“Merger Sub”). The merger contemplated by the Merger Agreement was implemented through a merger |
|
| January 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Standard BioTools Inc. |
|
| January 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Standard BioTools Inc. |
|
| January 12, 2024 |
FLDM / Standard BioTools Inc / Neuberger Berman Group LLC Activist Investment SC 13D/A 1 formsc13da-01122024070144.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* STANDARD BIOTOOLS INC. (Name of Issuer) Common (Title of Class of Securities) 34385P108 (CUSIP Number) William Braverman ESQ Neuberger Berman Group LLC 1290 Avenue of the Americas New York , New Jersey 10104 212 |
|
| January 12, 2024 |
EX-1 2 ex1-01122024070144.htm Exhibit 1 Schedule 1 Information with respect to transactions effected during the past sixty days or since the most recent filing on Schedule 13D (Unless noted otherwise, all transactions were effected on the New York Stock Exchange) Neuberger Berman Group LLC Date Buys/Sell Units Quantity Average Price 11/13/2023 Sell 69 2.20 11/14/2023 Buy 479 2.25 11/14/2023 Sell 1 |
|
| January 9, 2024 |
FLDM / Standard BioTools Inc / Casdin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 9, 2024 |
FLDM / Standard BioTools Inc / VIKING GLOBAL INVESTORS LP - SC 13G Passive Investment SC 13G 1 ef20018465sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. ) Standard BioTools Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of |
|
| January 8, 2024 |
FLDM / Standard BioTools Inc / Caligan Partners LP - STANDARD BIOTOOLS, INC. Activist Investment SC 13D/A 1 p24-0050sc13da.htm STANDARD BIOTOOLS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 7)* Standard BioTools, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (T |
|
| January 8, 2024 |
Exhibit 99.2 Standard BioTools Activating a Strategy to Become a Diversified Leader in Life Sciences Tools J A N U A R Y 2 0 2 4 Standard BioTools Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the fo |
|
| January 8, 2024 |
Exhibit 99.1 Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue Achieving scale with pro forma full year 2023 revenue of approximately $192 million SOUTH SAN FRANCISCO, Calif., January 8, 2024 - Standard BioTools Inc. (Nasdaq: LAB) (Standard BioTools or the Company), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announ |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 5, 2024 |
Standard BioTools Stockholders Approve Merger with SomaLogic Exhibit 99.1 Standard BioTools Stockholders Approve Merger with SomaLogic SOUTH SAN FRANCISCO, Calif., January 4, 2024 - Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (Nasda |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2024 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 5, 2024 |
Exhibit 99.2 Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives SOUTH SAN FRANCISCO, Calif., January 5, 2024 - Standard BioTools Inc. (Nasdaq: LAB), driven by |
|
| January 5, 2024 |
Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan. Exhibit 10.1 STANDARD BIOTOOLS INC. 2011 EQUITY INCENTIVE PLAN (as amended and restated effective June 3, 2019, and as further amended effective June 23, 2020, May 25, 2021, June 14, 2023 and January 4, 2024) 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentive |
|
| January 5, 2024 |
Exhibit 3.1 SECOND CERTIFICATE OF AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF STANDARD BIOTOOLS INC. Standard BioTools Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies that: 1. Section 1 of Article IV of the Eighth Amended and Res |
|
| December 29, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 29, 2023 |
Exhibit 99.1 Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif. - December 29, 2023 – Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that a second leading independent proxy advisory firm, Glass, Lewis & Co |
|
| December 29, 2023 |
Exhibit 99.1 Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif. - December 29, 2023 – Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that a second leading independent proxy advisory firm, Glass, Lewis & Co |
|
| December 26, 2023 |
Exhibit 99.1 ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif. - December 22, 2023 – Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services |
|
| December 26, 2023 |
Exhibit 99.1 ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif. - December 22, 2023 – Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services |
|
| December 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 22, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-275533 Standard BioTools Inc. (“Standard BioTools”) has filed a registration statement on Form S-4, as amended (File No. 333-275533) (the “Registration Statement”), with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. The Registration Statement relates to an offering of securities o |
|
| December 19, 2023 |
Exhibit 99.3 Dear First Last Name: Standard BioTools Inc.’s Special Meeting of Stockholder is fast approaching, and according to our records we have not received your vote. As previously announced by The Company, Standard BioTools Inc. have entered into an Agreement and Plan of Merger with SomaLogic, Inc. and the Merger cannot be consummated unless the stockholders of Standard BioTools, Inc. appro |
|
| December 19, 2023 |
Exhibit 99.3 Dear First Last Name: Standard BioTools Inc.’s Special Meeting of Stockholder is fast approaching, and according to our records we have not received your vote. As previously announced by The Company, Standard BioTools Inc. have entered into an Agreement and Plan of Merger with SomaLogic, Inc. and the Merger cannot be consummated unless the stockholders of Standard BioTools, Inc. appro |
|
| December 19, 2023 |
Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023 Exhibit 99.1 Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023 Legal Information 3 (1) Assumes transaction close in Q1 2024. Total cost synergies exclude non - cash, restructuring - related and other non - recurring costs for each of Standard BioTools and SomaLogic. (2) Based on assumed Q1 2024 close and estimated combined cash balance of Standard BioTools and SomaLogic, le |
|
| December 19, 2023 |
Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023 Exhibit 99.1 Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023 Legal Information 3 (1) Assumes transaction close in Q1 2024. Total cost synergies exclude non - cash, restructuring - related and other non - recurring costs for each of Standard BioTools and SomaLogic. (2) Based on assumed Q1 2024 close and estimated combined cash balance of Standard BioTools and SomaLogic, le |
|
| December 19, 2023 |
Exhibit 99.2 Hi {fname}! This is {agentfirstname} with Alliance Advisors, on behalf of your investment with Standard BioTools, Inc., and the Board of Directors. Standard BioTools Inc.’s Special Meeting of Stockholder is fast approaching, and according to our records we have not received your vote. As previously announced by The Company, Standard BioTools Inc. have entered into an Agreement and Pla |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 19, 2023 |
Exhibit 99.2 Hi {fname}! This is {agentfirstname} with Alliance Advisors, on behalf of your investment with Standard BioTools, Inc., and the Board of Directors. Standard BioTools Inc.’s Special Meeting of Stockholder is fast approaching, and according to our records we have not received your vote. As previously announced by The Company, Standard BioTools Inc. have entered into an Agreement and Pla |
|
| December 19, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission |
|
| December 4, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission |
|
| December 4, 2023 |
Exhibit 99.1 Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., December 4, 2023 - Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, |
|
| December 4, 2023 |
Exhibit 99.1 Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., December 4, 2023 - Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, |
|
| December 1, 2023 |
Consent of Perella Weinberg Partners L.P. Exhibit 99.4 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated October 4, 2023 appearing as Annex C to, and the reference to such opinion letter under the headings “Prospectus Summary—Opinion of SomaLogic’s Financial Advisor” and “The Merger—Opinion of SomaLogic Financial Advisor” in, Amendment No. 1 to the Registration Statement on Form S-4 of Stand |
|
| December 1, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| December 1, 2023 |
Form of Proxy Card to be used by holders of capital stock of Standard BioTools Inc. Exhibit 99.1 1 1 12345678 12345678 12345678 12345678 12345678 12345678 12345678 12345678 NAME THE COMPANY NAME INC. - COMMON 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS A 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS B 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS C 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS D 123,456,789,012.12345 THE COMPANY NAME INC. - CLASS E 123,4 |
|
| December 1, 2023 |
Form of Proxy Card to be used by holders of common stock of SomaLogic, Inc. Exhibit 99.2 YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: SomaLogic, Inc. Special Meeting of Stockholders For Stockholders of record as of November 29, 2023 DATE: Thursday, January 4, 2024 TIME: 10:00 AM, Mountain Time PLACE: Annual Meeting to be held live via the Internet- Please visit www.proxydocs.com/SLGC for more details. This proxy is being solicited on behalf of the Board of Directors The unders |
|
| December 1, 2023 |
MERGER PROPOSAL — YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-275533 MERGER PROPOSAL — YOUR VOTE IS VERY IMPORTANT December 1, 2023 Dear Stockholders of Standard BioTools Inc. and Stockholders of SomaLogic, Inc.: As previously announced, the boards of directors of Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), and SomaLogic, Inc., a Delaware corporation (“SomaLog |
|
| December 1, 2023 |
Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA December 1, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart RE: Standard BioTools Inc. Registration Statement on Form S-4, as amended, File No. 333-275533 Request f |
|
| December 1, 2023 |
Consent of Centerview Partners LLC. Exhibit 99.3 Centerview Partners LLC 31 West 52nd Street New York, NY 10019 November 30, 2023 The Board of Directors Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA 94080 The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated October 4, 2023, to the Board of Directors of Standard BioTools Inc. (“Standard BioTools”) as Annex B to, and refere |
|
| November 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| November 29, 2023 |
Exhibit 99.1 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools NOVEMBER 2023 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements, ma |
|
| November 29, 2023 |
Exhibit 99.1 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools NOVEMBER 2023 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements, ma |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| November 22, 2023 |
FLDM / Standard BioTools Inc / VIKING GLOBAL INVESTORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* STANDARD BIOTOOLS INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34385P108 (CUSIP Number) Andrew Genser General Counsel 600 Washington Boulevard, Floor 11 Stamford, Connecticut 06901 (212) 672-7050** (Name, |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| November 14, 2023 |
Exhibit 99.10 November 13, 2023 Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA 94080 Consent of Person Named as About to Become Director Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the registration statement on Form S-4 of Standard BioTools Inc. (the “Company”), and all amendments thereto (the “Regis |
|
| November 14, 2023 |
Exhibit 99.11 November 13, 2023 Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA 94080 Consent of Person Named as About to Become Director Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the registration statement on Form S-4 of Standard BioTools Inc. (the “Company”), and all amendments thereto (the “Regis |
|
| November 14, 2023 |
Consent of Perella Weinberg Partners L.P. Exhibit 99.4 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated October 4, 2023 appearing as Annex C to, and the reference to such opinion letter under the headings “Prospectus Summary—Opinion of SomaLogic’s Financial Advisor” and “The Merger—Opinion of SomaLogic Financial Advisor” in, the Registration Statement on Form S-4 of Standard BioTools Inc. a |
|
| November 14, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 14, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-4 (Form Type) Standard BioTools Inc. |
|
| November 14, 2023 |
Offer letter, by and between Standard BioTools Inc. and Adam Taich, dated as of October 1, 2023. Exhibit 10.1 October 1, 2023 Dear Adam: We are pleased to offer you employment with Standard BioTools Inc. (the “Company”) contingent upon the closing of the transactions (the “Transaction”) contemplated by the Agreement and Plan of Merger between SomaLogic, Inc., the Company, and certain other parties (the “Transaction Agreement”). If the Transaction does not occur, this offer is null and void. T |
|
| November 14, 2023 |
Exhibit 99.9 November 13, 2023 Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA 94080 Consent of Person Named as About to Become Director Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, I hereby consent to my being named in the registration statement on Form S-4 of Standard BioTools Inc. (the “Company”), and all amendments thereto (the “Regist |
|
| November 14, 2023 |
Consent of Centerview Partners LLC. Exhibit 99.3 Centerview Partners LLC 31 West 52nd Street New York, NY 10019 November 13, 2023 The Board of Directors Standard BioTools Inc. 2 Tower Place, Suite 2000 South San Francisco, CA 94080 The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated October 4, 2023, to the Board of Directors of Standard BioTools Inc. (“Standard BioTools”) as Annex B to, and refere |
|
| November 13, 2023 |
Matthew J. Gardella 617 348 1735 [email protected] One Financial Center Boston, MA 02111 617 542 6000 mintz.com November 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Standard BioTools Inc. - Registration Statement on Form S-4 Ladies and Gentlemen: On behalf of our client, Standard BioTools Inc., |
|
| November 8, 2023 |
Filed by Standard BioTools Inc. Filed by Standard BioTools Inc. Commission File No.: 001-34180 Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: SomaLogic, Inc. Commission File No.: 001-40090 On November 7, 2023, Standard BioTools Inc. (“Standard BioTools”) issued a press release reporting its financia |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STAND |
|
| November 7, 2023 |
Exhibit 99.1 Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results • Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against financial objectives • Planned merger with SomaLogic activates strategic M&A thesis SOUTH SAN FRANCISCO, Calif., November 7, 2023 — Standard BioTools Inc. (“SBI” or the “Compan |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-34180 (Commi |
|
| October 16, 2023 |
EX-99.1 2 ef20012105ex99-1.htm EXHIBIT 1 EXHIBIT 1 - JOINT FILING AGREEMENT This joint filing agreement is made and entered into as of this 16th day of October, 2023, by and among Viking Global Investors LP, Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, Vik |
|
| October 16, 2023 |
FLDM / Standard BioTools Inc / VIKING GLOBAL INVESTORS LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* STANDARD BIOTOOLS INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34385P108 (CUSIP Number) Andrew Genser General Counsel 600 Washington Boulevard, Floor 11 Stamford, Connecticut 06901 203-863-7050 (Name, Addre |
|
| October 4, 2023 |
Exhibit 99.2 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools O C T O B E R 4 , 2 0 2 3 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements |
|
| October 4, 2023 |
Exhibit 99.4 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), SomaLogic, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signa |
|
| October 4, 2023 |
Standard BioTools announces merger with Somalogic Filed by Standard BioTools Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Standard BioTools Inc. Commission File No.: 001-34180 Standard BioTools announces merger with Somalogic Dear Valued Supplier, As a valued supplier/vendor of Standard BioTools, I am writing |
|
| October 4, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among SOMALOGIC, INC., STANDARD BIOTOOLS INC., and MARTIS MERGER SUB, INC. Dated as of October 4, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGER; CLOSING; SURVIVING COMPANY 2 1.1 The Merger 2 1.2 Closing 2 1.3 Effective Time 2 1.4 The Certificate of Incorporation 2 1.5 The Bylaws 3 1.6 Directors and Officers of Parent 3 1.7 Directors and Officers of the S |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 4, 2023 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 4, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among SOMALOGIC, INC., STANDARD BIOTOOLS INC., and MARTIS MERGER SUB, INC. Dated as of October 4, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGER; CLOSING; SURVIVING COMPANY 2 1.1 The Merger 2 1.2 Closing 2 1.3 Effective Time 2 1.4 The Certificate of Incorporation 2 1.5 The Bylaws 3 1.6 Directors and Officers of Parent 3 1.7 Directors and Officers of the S |
|
| October 4, 2023 |
Exhibit 99.4 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), SomaLogic, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signa |
|
| October 4, 2023 |
Exhibit 99.2 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools O C T O B E R 4 , 2 0 2 3 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements |
|
| October 4, 2023 |
Exhibit 99.1 Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach |
|
| October 4, 2023 |
Standard BioTools announces merger with Somalogic Filed by Standard BioTools Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Standard BioTools Inc. Commission File No.: 001-34180 Standard BioTools announces merger with Somalogic Dear Valued Customer, I am writing to share the news (https://investors.standardbio.c |
|
| October 4, 2023 |
Exhibit 99.3 Execution Version VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), SomaLogic, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedu |
|
| October 4, 2023 |
Exhibit 99.5 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among SomaLogic, Inc., a Delaware corporation (the “Company”), Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the persons listed on the attached Schedule A who are signa |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 4, 2023 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 4, 2023 |
Exhibit 99.3 Execution Version VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), SomaLogic, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedu |
|
| October 4, 2023 |
Filed by Standard BioTools Inc. Filed by Standard BioTools Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Standard BioTools Inc. Commission File No.: 001-34180 Who is Somalogic? “SomaLogic (Nasdaq: SLGC) is fostering the discovery of effective and safer treatments for patients in need while emp |
|
| October 4, 2023 |
Pursuant to Rule 425 under the Securities Act of 1933, as amended, Filed by Standard BioTools Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Standard BioTools Inc. Commission File No.: 001-34180 Operator: Good morning and welcome to today’s Standard BioTools and SomaLogic merger announcement conference call. Before market open t |
|
| October 4, 2023 |
Exhibit 99.5 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among SomaLogic, Inc., a Delaware corporation (the “Company”), Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the persons listed on the attached Schedule A who are signa |
|
| October 4, 2023 |
Filed by Standard BioTools Inc. Filed by Standard BioTools Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Standard BioTools Inc. Commission File No.: 001-34180 Dear LABsters, This morning, we announced our intent to merge with SomaLogic, (NASDAQ: SLGC), a company that shares our mission to powe |
|
| October 4, 2023 |
Exhibit 99.1 Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2023 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2023 |
Offer letter, by and between Standard BioTools Inc. and Jeremy Davis, dated April 4, 2023. Exhibit 10.10 April 4, 2022 Jeremy Davis 320 Park Street S, St Petersburg, FL 33707 Dear Jeremy: We are pleased to offer you employment with Fluidigm Corporation (“Fluidigm” or the “Company”) contingent upon the closing of the private placement of Fluidigm’s convertible preferred stock to Casdin Capital, LLC and Viking Global Investors LP and/or one or more of their respective affiliates (the “Tra |
|
| August 8, 2023 |
Standard BioTools Reports Second Quarter 2023 Financial Results Continued operational execution improves revenue growth, margin expansion, and expense reduction SOUTH SAN FRANCISCO, Calif. |
|
| August 8, 2023 |
Exhibit 10.9 Executive Leadership Team Members Appendix A Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement Standard BioTools Inc. (the “Company”) is pleased to inform you that you have been selected to participate in the Company’s 2023 Change of Control and Severance Plan (the “Plan”) as a Participant. A copy of the Plan was delivered to you with this Partic |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STANDARD B |
|
| August 8, 2023 |
Exhibit 10.11 Executive Leadership Team Members Appendix A Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement Standard BioTools Inc. (the “Company”) is pleased to inform you that you have been selected to participate in the Company’s 2023 Change of Control and Severance Plan (the “Plan”) as a Participant. A copy of the Plan was delivered to you with this Parti |
|
| July 28, 2023 |
Exhibit 10.3 STANDARD BIOTOOLS INC. 2011 EQUITY INCENTIVE PLAN PERFORMANCE UNIT AWARD AGREEMENT (U.S. participants) Unless otherwise defined in this Performance Unit Award Agreement, including the Terms and Conditions of Performance Unit Grant attached hereto as Exhibit A (collectively, the “Award Agreement”), all capitalized terms have the meanings given to them in the Standard BioTools Inc. 2011 |
|
| July 28, 2023 |
2023 Change of Control and Severance Plan. Exhibit 10.1 STANDARD BIOTOOLS INC. 2023 CHANGE OF CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Adopted August 4, 2023 1.Introduction. The purpose of this Standard BioTools Inc. 2023 Change of Control and Severance Plan, or Plan (as defined in Section 2 below), is to provide assurances of specified benefits to certain employees of the Company whose employment is subject to being involun |
|
| July 28, 2023 |
Exhibit 10.2 CEO Participation Agreement Appendix A Standard BioTools Inc. 2023 Change of Control and Severance Plan Participation Agreement Standard BioTools Inc. (the “Company”) is pleased to inform you that you have been selected to participate in the Company’s 2023 Change of Control and Severance Plan (the “Plan”) as a Participant. A copy of the Plan was delivered to you with this Participatio |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2023 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Standard BioTools Inc. (Name of Issuer) COM (Title of Class of Securities) 34385P108 (CUSIP Number) June 30, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| July 3, 2023 |
FLDM / Standard BioTools Inc / Caligan Partners LP - STANDARD BIOTOOLS, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 6)* Standard BioTools, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) |
|
| June 20, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| June 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Standard BioTools Inc. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 Standard BioTools Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 16, 2023 |
Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan. Exhibit 10.1 STANDARD BIOTOOLS INC. 2011 EQUITY INCENTIVE PLAN (as amended and restated effective June 3, 2019, and as further amended effective June 23, 2020, May 25, 2021 and June 14 2023) 1.Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentive to Employees, Direc |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Standard BioTools Inc. (Exact name of the registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2 Tower Place, Suite 2000, South San Francisco, California 94080 (Addres |
|
| May 26, 2023 |
Standard BioTools Inc. Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Standard BioTools Inc. (formerly, Fluidigm Corporation) Conflict Minerals Report For The Reporting Period from January 1, 2022 to December 31, 2022 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning Standard |
|
| May 15, 2023 |
Letter Agreement, dated as of May 10, 2023, by and between Standard BioTools Inc. and Vikram Jog. EXHIBIT 10.3 STANDARD BIOTOOLS INC. May 10, 2023 Vikram Jog 10645 Eloise Circle Los Altos Hills, CA 94024 Dear Vikram: This letter agreement (this “Agreement”) sets forth the terms and conditions relating to certain benefits that you may become eligible to receive in the event of your termination of employment from Standard BioTools Inc. (the “Company”). For valuation consideration, the receipt an |
|
| May 15, 2023 |
EXHIBIT 99.1 Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 — Standard BioTools Inc. (Nasdaq: LAB), driven by a b |
|
| May 15, 2023 |
Jeffery G. Black Offer Letter. EXHIBIT 10.1 Join an innovative team driven by a bold vision – unleashing tools to accelerate breakthroughs in human health May 9, 2023 Jeff Black 4132 Garfield Street Carlsbad, CA 92008 Dear Jeff: We are pleased to offer you the position of Senior Vice President and Chief Financial Officer with Standard BioTools Inc, reporting to Michael Egholm, Chief Executive Officer and President. You will per |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 10, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 15, 2023 |
EXHIBIT 10.2 Executive Leadership Team Members Appendix A Standard BioTools Inc. 2020 Change of Control and Severance Plan Participation Agreement Standard BioTools Inc. (the “Company”) is pleased to inform you that you have been selected to participate in the Company’s 2020 Change of Control and Severance Plan (the “Plan”) as a Participant. A copy of the Plan was delivered to you with this Partic |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission File |
|
| May 9, 2023 |
Standard BioTools Reports First Quarter 2023 Financial Results EXHIBIT 99.1 Standard BioTools Reports First Quarter 2023 Financial Results Net cash used in operating activities of $8.5 million, a 55.8% sequential decline from $19.2 million in the fourth quarter and a 46% reduction from the $15.6 in the first quarter last year GAAP revenue (includes discontinued/COVID-19 products) decreased 5.2% year-over-year to $25.1 million, with a 1.8% year-over-year incre |
|
| May 9, 2023 |
exhibit101-sbifirstdata -1- 4855-3141-1533.2 - 2/27/2023 3:13:45 PM SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of February 28, 2023, and is made by and between STANDARD BIOTOOLS INC., a Delaware corporation (formerly known as Fluidigm Corporation) (“Sublessor”), and FIRST DATABANK, INC., a Missouri corporation (“Sublessee”). Sublessor and Sublessee hereby agree as |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STANDARD |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission F |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission F |
|
| March 16, 2023 |
Experienced Life Science Operating Leader Joins Board as Company Enters New Phase EXHIBIT 99.1 Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors March 15, 2023 Experienced Life Science Operating Leader Joins Board as Company Enters New Phase SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) - Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appo |
|
| March 14, 2023 |
Subsidiaries of Standard BioTools Inc. EX-21.1 3 exhibit2112022subsidiaries1.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF STANDARD BIOTOOLS INC. Subsidiaries of Standard BioTools Inc. (Delaware): SB Sciences Inc. (Delaware) Standard BioTools (Shanghai) Instrument Technology Company Limited (China) Standard BioTools K.K. (Japan) Standard BioTools Europe B.V. (Netherlands) Standard BioTools Singapore Pte. Ltd. (Singapore) Subsidiaries of Sta |
|
| March 14, 2023 |
Standard BioTools Inc. and each of its officers and sbi-indemnificationagree STANDARD BIOTOOLS INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [DATE] by and between Standard BioTools Inc., a Delaware corporation (the “Company”), and [NAME] (“Indemnitee”). WHEREAS, the Company and Indemnitee recognize the significant cost of directors’ and officers’ liability insurance and the general reductions in the cover |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2023 |
FLDM / Fluidigm Corporation / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 brhc10048011sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Standard BioTools Inc. (Name of Issuer) Common stock, $0.001 par value per share (T |
|
| February 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 14, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| February 14, 2023 |
FLDM / Fluidigm Corporation / North Sound Trading, LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 eh23032937213ga1-lab.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Standard Biotools Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34385P108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this St |
|
| February 14, 2023 |
EXHIBIT 99.1 Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook Fourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product and service revenues of $94.5 million Improved operating discipline and res |
|
| February 14, 2023 |
FLDM / Fluidigm Corporation / Indaba Capital Management, L.P. Passive Investment SC 13G/A 1 formsc13ga-standard.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Standard BioTools Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 9, 2023 |
FLDM / Fluidigm Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01953-standardbiotoolsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Standard BioTools Inc. Title of Class of Securities: Common Stock CUSIP Number: 34385P108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to d |
|
| February 9, 2023 |
SC 13G 1 lab20923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Standard BioTools Inc. (Name of Issuer) COM (Title of Class of Securities) 34385P108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 9, 2023 |
Standard BioTools Corporate Presentation January 2023 EX-99.2 3 eh230318897ex9902.htm EXHIBIT 99.2 EXHIBIT 99.2 Standard BioTools Corporate Presentation January 2023 Legal information 2 Forward - Looking Statements This presentation and the accompanying oral presentation contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the expected advantages |
|
| January 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 9, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2023 |
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update EXHIBIT 99.1 Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update Continued commercial and strategic execution delivers sequential core revenue growth of 4%–9% to $26 million–$27 million in Q4 2022 for full year total of approximately $94 million–$95 million Business restructuring and SBS program on track to deliver over 20% reduction in operating expenses or more |
|
| December 30, 2022 |
FLDM / Fluidigm Corporation / Caligan Partners LP - STANDARD BIOTOOLS INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 5)* Standard BioTools, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34385P108 (CUSIP Number) |
|
| November 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 28, 2022 Standard BioTools Inc. |
|
| November 28, 2022 |
Standard BioTools Authorizes up to $20 Million of Share Repurchases EXHIBIT 99.1 Standard BioTools Authorizes up to $20 Million of Share Repurchases November 28, 2022 SOUTH SAN FRANCISCO, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) - Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose ??unleashing tools to accelerate breakthroughs in human health ? today announced that its board of directors has authorized the repurchase of up to $20 million of shares of its |
|
| November 14, 2022 |
FLDM / Fluidigm Corporation / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* STANDARD BIOTOOLS INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 34385P108 (CUSIP Number) November 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| November 9, 2022 |
Sublease, dated as of August 30, 2022, by and between Standard BioTools Inc. and CIRC Bio, Inc. Exhibit 10.1 SUBLEASE THIS SUBLEASE (this ?Sublease?) is dated for reference purposes as of August 30, 2022, and is made by and between STANDARD BIOTOOLS INC., a Delaware corporation (formerly known as Fluidigm Corporation) (?Sublessor?), and CIRC BIO, INC., a Delaware corporation (?Sublessee?). Sublessor and Sublessee hereby agree as follows: 1.Recitals: This Sublease is made with reference to th |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STAND |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2022 |
Standard BioTools Announces Third Quarter 2022 Financial Results EXHIBIT 99.1 Standard BioTools Announces Third Quarter 2022 Financial Results Third quarter core product and services revenue increase of 30% sequentially to $24.8 million First phase of restructuring program improves operating margin by 600 to 800 basis points, or $8.0 million net on an annualized basis Reiterate stated goal of 700 to 1000 basis point non-GAAP product and service gross margin imp |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34180 STANDARD B |
